|
NFCR commits $1 million in financing to Rasio Therapeutics to develop treatments targeting cancers with limited treatment options
November 25, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the launch of a formal partnership with the National Foundation for Cancer Research (NFCR).
Chappell is a 20-year veteran of the biopharma industry with experience running multiple drug development programs from discovery stage through to clinical trials
November 14, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the appointment of Todd Chappell, a veteran medtech and pharmaceutical industry executive, as the company’s CEO. |
